A Phase I/II Study of MRTX849 in Patients with KRAS G12C-positive Cancers


Full Title

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation


The purpose of this study is to determine the highest dose of the investigational drug MRTX849 that can be given safely in patients with advanced non-small cell lung cancer (NSCLC) or colorectal cancer that has a mutation in the KRAS G12C gene. MRTX849 is designed to inhibit cancer growth by blocking this defective gene. MRTX849 is taken orally (by mouth).

Who Can Join

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have NSCLC or colorectal cancer that has come back or continued to grow despite standard therapies and contains a KRAS G12C mutation.
  • At least 2 weeks must pass since the completion of prior therapy and entry into the study.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self-care, and capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • This study is for patients age 18 and older.

For more information and to inquire about eligibility for this study, please contact Dr. Gregory Riely at 646-888-4199.




Phase I/II (phases 1 and 2 combined)

Disease Status

Relapsed or Refractory



ClinicalTrials.gov ID